|
PPP2CA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.35039987472874E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.74070013747985E-10 |
| Normal-vs-Stage2 |
1.717550E-02 |
| Normal-vs-Stage3 |
2.5519999446999E-09 |
| Normal-vs-Stage4 |
6.97389923587366E-11 |
| Stage1-vs-Stage2 |
2.752800E-01 |
| Stage1-vs-Stage3 |
1.157000E-01 |
| Stage1-vs-Stage4 |
8.552200E-04 |
| Stage2-vs-Stage3 |
8.314000E-02 |
| Stage2-vs-Stage4 |
1.090300E-02 |
| Stage3-vs-Stage4 |
1.364620E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.68274333040608E-12 |
| Normal-vs-AfricanAmerican |
1.243060E-03 |
| Normal-vs-Asian |
2.46749999988083E-07 |
| Caucasian-vs-AfricanAmerican |
6.460200E-01 |
| Caucasian-vs-Asian |
9.333200E-01 |
| AfricanAmerican-vs-Asian |
7.495200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.93869999995677E-06 |
| Normal-vs-Female |
1.9274026819005E-11 |
| Male-vs-Female |
3.880000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.0785999828924E-09 |
| Normal-vs-Age(41-60Yrs) |
6.44319999576481E-08 |
| Normal-vs-Age(61-80Yrs) |
2.83300000125664E-08 |
| Normal-vs-Age(81-100Yrs) |
1.859550E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.650600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.518600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.662400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.777400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.800000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.227000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.681190E-03 |
| Classical-VS-Follicular |
4.457200E-01 |
| Classical-VS-Other |
4.922200E-01 |
| Classical-VS-Normal |
1.46769999487262E-08 |
| Tall-VS-Follicular |
1.122120E-03 |
| Tall-VS-Other |
4.665800E-01 |
| Tall-VS-Normal |
8.41460012779294E-10 |
| Follicular-VS-Other |
3.421800E-01 |
| Follicular-VS-Normal |
2.30900000000034E-05 |
| Other-VS-Normal |
7.717600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11930000046279E-07 |
| Normal-vs-N1 |
2.95860003163284E-10 |
| N0-vs-N1 |
1.590370E-02 |
|
|
